GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » InnoCan Pharma Corp (XCNQ:INNO) » Definitions » Short Interest

InnoCan Pharma (XCNQ:INNO) Short Interest


View and export this data going back to 2019. Start your Free Trial

What is InnoCan Pharma Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of InnoCan Pharma's Short Interest

For the Drug Manufacturers - Specialty & Generic subindustry, InnoCan Pharma's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InnoCan Pharma's Short Interest Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, InnoCan Pharma's Short Interest distribution charts can be found below:

* The bar in red indicates where InnoCan Pharma's Short Interest falls into.


InnoCan Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » InnoCan Pharma Corp (XCNQ:INNO) » Definitions » Short Interest
Comparable Companies
TSXV:LOVE TSX:CRDL TSXV:RX XCNQ:GRIN TSXV:ZYUS TSX:CPH TSXV:DB XCNQ:JUSH XCNQ:AYR.A XCNQ:HUGE ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
INNPF:USA IP4:Germany
Address
1015, 926 - 5 Avenue SW, Calgary, AB, CAN, T2P 0N7
Website
https://www.innocanpharma.com
InnoCan Pharma Corp is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals. Geographically, it derives a majority of its revenue from the United States.
Executives
Peter David Bloch Director
William Colin Macdonald Director

InnoCan Pharma Headlines